Trial Profile
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 17 Aug 2023
Price :
$35
*
At a glance
- Drugs Ertugliflozin (Primary) ; Glipizide
- Indications Cardiovascular disorders; Diabetes mellitus
- Focus Pharmacodynamics
- 10 Aug 2023 Planned End Date changed from 31 Jul 2022 to 31 Dec 2023.
- 10 Aug 2023 Planned primary completion date changed from 31 Jul 2022 to 31 Dec 2023.
- 10 Aug 2023 Status changed from recruiting to active, no longer recruiting.